Tau-Targeting Drug Davunetide Washes Out in Phase 3 Trials
Allon Therapeutics Inc. announced that its drug candidate davunetide failed to show efficacy for progressive supranuclear palsy (PSP) in a Phase 2/3 trial...
ALL NEWS
328 RESULTS
Sort By:
- Most Recent
- Most Commented
Will Technology Revolutionize Dementia Diagnosis and Care?
As populations age worldwide and the number of people with dementia is set to soar over the next few decades, a crisis in eldercare looms. At the same time, the use of personal technology—smartphones, tablets, wearable monitors—is exploding. Can technolog
Tech Revolution: Monitoring and the Power of Real-Time Data
Today, monitoring systems are commercially available from companies, and in use in many retirement and assisted-living communities...
Microglia and AD—Does the Inflammasome Drive Aβ Pathology?
Researchers have found a new microglial link between Aβ and neuroinflammation, two hallmarks of Alzheimer’s disease...
First Crystal Structure of a Presenilin
In this week’s Nature, researchers report the first successful crystal structure of a bacterial presenilin homologue...
Will Technology Revolutionize Dementia Diagnosis and Care?
Some researchers envision a future in which older adults with cognitive decline or Alzheimer’s disease could stay independent longer with the help of technology...
Research Brief: Around the Globe, More People Die of Dementia
Deaths due to Alzheimer’s disease and related dementias have jumped more than threefold worldwide since 1990...
Insurance Coverage of AD Diagnostics? Not Without Better Data
The quest for health insurance coverage of brain amyloid scanning just took a twist...
Does ApoE4 Lower Brain Metabolism Independently of Aβ?
Chalk another one up for the “not-all-about-amyloid” camp...
Waste Not, Want Not—Making Human Neurons From Urine
You may not like peeing in a cup at the doctor’s office, but what if it made stem cell creation a breeze?...
Q&A With Merck’s Johan Luthman
Merck’s BACE inhibitor development program began enrolling last month for an 18-month Phase 2/3 trial of its lead compound (MK-8931) in mild to moderate AD...
Solanezumab Heads for New Phase 3 Trial
Eli Lilly announced yesterday that it plans to conduct a new Phase 3 trial of its anti-amyloid antibody, solanezumab...
Natural History-Cum-Trials Initiative, Grants to Boost Down’s Research
Down’s syndrome (DS) and Alzheimer’s disease (AD) are inextricably linked...
Current Filters
- Date Range : Dec 2012 to Dec 2013 x